The JAK1-selective inhibitor upadacitinib successfully improved the signs, symptoms and function of rheumatoid arthritis patients in a randomized clinical trial published this month in Arthritis and Rheumatology.
Rheumatology Network Editorial Staff
In today's health quiz, we highlight some of the most recent scientific advances in psoriatic arthritis research. Click here to test your knowledge.
A 20-year analysis of hospitalizations due to compliations from systemic lupus erythematosus, shows new patterns in hospitalization rates, disease complications and mortality. In this slideshow, we highlight the findings.
On Friday, the U.S. Food and Drug Administration approved apremilast (Otezla, Celgene) for the treatment of oral ulcers associated with Behçet’s disease, a rare, chronic, multisystem inflammatory condition that affects approximately five in 100,000 people in the U.S.
The European League Against Rheumatism has updated treatment guidelines for the management of large vessel vasculitis. Among the changes, the task force no longer recommends the routine use of antiplatelet or anticoagulant therapy. Learn more in this slideshow.
In this month's health quiz, we revisit some of our most popular articles published in recent weeks. This includes news reports on the safety and efficacy of baricitinib, upadacitinib effectiveness as monotherapy, inherited rheumatoid arthritis and our most popular story from this month: The sexual health of patients with musculoskeletal conditions.
A 28-year-old woman visited urgent care complaining of an erythematous rash. She also had a sore throat, spiking fever and arthralgias. What's your diagnosis?